Autolus Therapeutics plc

NasdaqGS:AUTL Stock Report

Market Cap: US$609.4m

Autolus Therapeutics Management

Management criteria checks 4/4

Autolus Therapeutics' CEO is Chris Itin, appointed in Mar 2016, has a tenure of 8.75 years. total yearly compensation is $2.45M, comprised of 22.5% salary and 77.5% bonuses, including company stock and options. directly owns 0.4% of the company’s shares, worth $2.44M. The average tenure of the management team and the board of directors is 3.2 years and 4.8 years respectively.

Key information

Chris Itin

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage22.5%
CEO tenure8.8yrs
CEO ownership0.4%
Management average tenure3.2yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market

Nov 21

Autolus: Start Thinking About Obe-Cel PDUFA -- And The (Baby) Bull Case

Sep 06

Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?

Aug 15
Is Autolus Therapeutics (NASDAQ:AUTL) Using Debt Sensibly?

Autolus Therapeutics: Major Inflection Point On The Horizon

Jul 31

Autolus Therapeutics: Trading Like Their Products Are Not Valuable, Which Is An Opportunity

May 14

We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely

Nov 06
We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

Jun 26
Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth

Mar 09
We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth

Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value?

Dec 12
Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value?

Autolus stock rises as Moderna uses option to license targeting technology for mRNA therapy

Oct 12

Autolus Therapeutics: Overlooked CAR-T Player With Key Catalysts Approaching

Aug 17

Autolus Therapeutics Q2 2022 Earnings Preview

Aug 03

Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

Apr 19
Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

CEO Compensation Analysis

How has Chris Itin's remuneration changed compared to Autolus Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$270m

Jun 30 2024n/an/a

-US$234m

Mar 31 2024n/an/a

-US$221m

Dec 31 2023US$2mUS$551k

-US$208m

Sep 30 2023n/an/a

-US$158m

Jun 30 2023n/an/a

-US$155m

Mar 31 2023n/an/a

-US$152m

Dec 31 2022US$3mUS$502k

-US$149m

Sep 30 2022n/an/a

-US$164m

Jun 30 2022n/an/a

-US$155m

Mar 31 2022n/an/a

-US$146m

Dec 31 2021US$3mUS$543k

-US$142m

Sep 30 2021n/an/a

-US$143m

Jun 30 2021n/an/a

-US$147m

Mar 31 2021n/an/a

-US$145m

Dec 31 2020US$4mUS$522k

-US$142m

Sep 30 2020n/an/a

-US$140m

Jun 30 2020n/an/a

-US$130m

Mar 31 2020n/an/a

-US$127m

Dec 31 2019US$5mUS$517k

-US$124m

Sep 30 2019n/an/a

-US$104m

Jun 30 2019n/an/a

-US$89m

Mar 31 2019n/an/a

-US$68m

Dec 31 2018n/an/a

-US$58m

Sep 30 2018US$2mUS$403k

-US$45m

Compensation vs Market: Chris's total compensation ($USD2.45M) is about average for companies of similar size in the US market ($USD3.24M).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Itin (60 yo)

8.8yrs

Tenure

US$2,449,092

Compensation

Dr. Christian Martin Itin, also known as Chris, Ph D., has been the Chief Executive Officer of Autolus Therapeutics Plc. (Former Name: Autolus Limited) since March 3, 2016.Dr. Itin has been Director of Au...

Leadership Team

NamePositionTenureCompensationOwnership
Christian Itin
CEO & Director8.8yrsUS$2.45m0.40%
$ 2.4m
Martin Pule
Founder10.3yrsno data0.26%
$ 1.6m
Robert Dolski
Senior VP & CFO1.3yrsno datano data
Christopher Vann
Senior VP & COO8.2yrsno data0.042%
$ 257.0k
David Brochu
Senior VP & Chief Technical Officer3.9yrsno data0%
$ 0
Alexander Swan
Senior VP & Chief Human Resources Officer3.2yrsno data0%
$ 0
Brent Rice
Senior VPno datano data0.0035%
$ 21.5k
Olivia Manser
Director of Investor Relationsno datano datano data
Alex Driggs
Senior VP of Legal Affairs & General Counsel and Secretary3.2yrsno datano data
Chris Williams
Chief Business Officerless than a yearno data0.0031%
$ 18.8k
Miranda Neville
Senior Vice President of Project Management1.4yrsno datano data
Veronica Hersberger
Senior Vice President of Medical Affairs1.9yrsno datano data

3.2yrs

Average Tenure

58.5yo

Average Age

Experienced Management: AUTL's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christian Itin
CEO & Director10.2yrsUS$2.45m0.40%
$ 2.4m
William Young
Independent Non-Executive Director3.1yrsUS$224.14k0%
$ 0
Michael Bonney
Chairman of the Boardless than a yearno datano data
Cynthia Butitta
Independent Non-Executive Director6.8yrsUS$209.89k0.0038%
$ 22.9k
John Berriman
Independent Non-Executive Director10.3yrsUS$207.98k0.051%
$ 312.2k
Martin Murphy
Independent Non-Executive Director10.3yrsUS$201.77k0%
$ 0
Joseph Anderson
Independent Non-Executive Director8.8yrsUS$207.98k0%
$ 0
Linda Bain
Independent Non-Executive Director6.5yrsUS$216.11k0%
$ 0
Robert Azelby
Non-Executive Directorless than a yearno data0%
$ 0
Robert Iannone
Non-Executive Director1.5yrsUS$171.92k0%
$ 0
Ravi Rao
Non-Executive Directorless than a yearno datano data
Elisabeth Leiderman
Non-Executive Directorless than a yearUS$16.22k0%
$ 0

4.8yrs

Average Tenure

58.5yo

Average Age

Experienced Board: AUTL's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 20:49
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Autolus Therapeutics plc is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ingrid GafanhãoBryan Garnier & Co
Rajan SharmaGoldman Sachs
Debjit ChattopadhyayH.C. Wainwright & Co.